Hikma Steps Out Of Colchicine Sales Ban Shadow, Maintains 20 Percent Growth Forecast

U.S. FDA's ban on unapproved colchicine will cut deeply into Jordanian drug maker Hikma's profits and could present some obstacles to the company. However, the London Stock Exchange-listed company vows to maintain an estimated 20 percent growth and expects to continue penetration for its core products in the U.S. generics market